FDA Approves Leqembi, Extending Alzheimer’s Treatment to More Patients
Medicare enrollees can get the anti-amyloid treatment as a result of the agency’s full approval. Source link
Dementia
New Alzheimer’s Drug Leqembi Will Be Out of Reach for Most Patients
HealthMedicare won’t pay for medicine under rule issued to restrict use of earlier drug whose approval generated controversy Source link
An Uneasy Use for Apple’s AirTags: Tracking a Loved One With Dementia
Michelle Hirschboeck was looking for a way to keep track of her husband, Paul, who has dementia. She settled on...
Alzheimer’s Drug Slows Disease Progression in Trial
The pharmaceutical companies said their drug lecanemab reduced cognitive and functional decline by 27%, compared with a placebo, over 18...
FDA Rejects Short Sellers’ Request to Halt Trials of Alzheimer’s Drug
The Food and Drug Administration has denied a petition by short sellers to halt clinical trials of an experimental Alzheimer’s...
Medicare to Pay for Biogen’s New Alzheimer’s Drug in Clinical-Trial Patients
Medicare officials said they would cover Biogen Inc.’s BIIB 2.64% controversial Alzheimer’s disease drug Aduhelm on the condition that patients...
Cleveland Clinic, Mount Sinai and Providence Won’t Give Biogen’s New Alzheimer’s Drug
Three large hospitals are declining to administer Biogen Inc.’s BIIB -6.79% new Alzheimer’s treatment, Aduhelm, the latest rupture to emerge...
FDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns
The U.S. Food and Drug Administration approved the first new Alzheimer’s drug in decades over the objection of agency statisticians...
Pill-Dispensing Tech Makes the Medicine Go Down…With Human Help, That Is
When Stephanie Luehrs’s father began losing track of what day it was, she knew his pre-filled pill packs were no...
Lilly Alzheimer’s Drug Shows Modest Benefit in Clinical Trial
An Eli Lilly LLY 1.40% & Co. experimental drug modestly slowed the cognitive and functional decline of early-stage Alzheimer’s patients...
